|09 January 2018|
|Health Care Sector Momentum Carried into First Week of January|
Singapore’s 10 largest capitalised Health Care stocks have averaged 3.3% price gains for the first five sessions of 2018, following on from an averaged 13.2% price gain in 2017. As detailed in the table below, the largest capitalised stock of the Health Care Sector is secondary listing IHH Healthcare Berhad which declined 9.3% last year. At the same time, the traded value of IHH Healthcare Berhad in 2017 was up 7.4%, from a relatively low base in 2016.
As IHH Healthcare Berhad makes up more than 50% of the market capitalisation of Singapore’s Health Care Sector its performance had a significant impact on the Health Care Sector’s 6.2% market capitalisation weighted total returns last year. The next five largest capitalised Health Care stocks after IHH Healthcare averaged 19.3% price gains in 2017. The 10 largest Healthcare stocks (excluding REITs and Business Trusts) are tabled below.
Note Riverstone Holdings is not categorised to the GICS® Health Care Sector
Source: SGX StockFacts, Bloomberg (Data as of 9 January 2018).
Top Glove Net Profit for 1QFY18 (ending 30 Nov) up 43.9% YoY
Of the 10 stocks tabled above, secondary listing Top Glove Corporation Berhad was the best performer over the first five sessions of 2017, in addition to 2016. For its 1QFY18 (ending 30 Nov) the Group reported its highest-ever quarterly sales revenue, at RM938.1 million, which represented a YoY increase of 19.4%. Its profit after tax, at RM105.9 million, rose 43.9% YoY. Management also reported that sales volumes (in terms of quantity sold) demonstrated growth of 17% YoY, which was led by nitrile glove sales volume. For more details click here.
The comparative price performances of the two REITS and the Business Trust investing in Health Care related properties are tabled below.
Note: ParkwayLife REIT and First REIT are REITs, whilst RHT Health Trust is a Business Trust. For more
information on both asset classes, click here. Source: SGX StockFacts, Bloomberg (Data as of 9 January 2018)
Clearbridge Health up 66% from IPO Price
On 18 December, Clearbridge Health listed on Catalist raising S$24.6 million and opening with market capitalisation of S$134.7 million. The stock ended yesterday at 46.5 cents, which was two-thirds higher than the IPO price of 28 cents.
Clearbridge Health specialises in the delivery of precision medicine in Asia in addition to providing laboratory and Health Care services. Its precision medical technology businesses include Clearbridge BioPhotonics which develops the next generation microscope technology; and Clearbridge BioMedics, which developed the ClearCell® FX System - one of the world’s first fully automated cell retrieval systems.
Comparative Sector Returns in 2017
As illustrated below, Singapore’s Cyclical Sectors all performed better than the Defensive Sectors in 2017.
2017 Indicative Market Cap-weighted Total Returns of 12 GICS® Sectors & Key Industries (%)
Note Delong Holdings 814% gain in 2017 accounted for more than half of the gains for the Materials Sector (or 43% of the 83%) in 2017, implying the remainder of the Materials Sector gained 40%. GICS ® Sector performance is weighed to market cap at the end of each period, is in SGD and includes reinvested dividends. Source: SGX StockFacts & Bloomberg.
Performances of the seven Cyclical Sectors ranged from a 107% market capitalisation weighted total return for Information Technology (“IT”) to a 17% market capitalisation weighted total return for Industrials. There was a 1% performance differential between the least performing Cyclical Sector (Industrials) and the best performing Defensive Sector (Utilities), which narrowed from a 7% differential as of the end of October
The Health Care Sector was the strongest of the Sectors in the last month of 2017, with market capitalisation total returns of 4.7%. The Sector has added 2.9%, using the same metrics, over the first five sessions of January 2018.
As noted above, market capitalisation weighted returns of the Health Care Sector are mostly weighted to the returns of IHH Healthcare Berhad as the stock accounted for 52% of the Health Care sector’s combined market capitalisation as of the end of 2017. By comparison Top Glove Corporation Berhad and Haw Par Corporation respectively accounted for 11% and 8% of the combined capitalisation.
2017 Indicative Monthly Market Cap-weighted Total Returns of 12 GICS® Sectors & Key Industries (%)
*Note Delong Holdings’ 145.0% gain in October accounted for almost three quarters of the gains of the Materials Sector (or 10.9% of the 15.2%) implying the remainder of the Materials Sector gained 4.3%. For monthly data, the Indicative GICS® Sector performance is weighed to market cap at each month end, is in SGD terms and includes reinvested dividends. Source: SGX StockFacts & Bloomberg.
The indicative sum of the best performing sectors for each of the 12 months across 2017 was a total return of 88%. As illustrated above, the 88% total return, weighed to market capitalisation, started with the Industrials Sector returning 7.5% in January and ended with Health Care adding 4.7% in December. The combined decline for the least performing Sector of each of the last 12 months was 37%. By comparison, over the 12 months the STI generated a total return of 22%. Note this does not include any transactions fees which would be associated with the sector rotation.
|My Gateway & SGX StockFacts|
SGX’s investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.
Whether you are seeking new or established companies to invest in, SGX StockFacts can provide you with the information you need to identify and understand the stocks that best fit your investment strategy. Visit now at sgx.com/stockfacts.
This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the “SGX Group Companies”) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.
Nikkei owns the copyright and any other intellectual property rights in the Nikkei Stock Average itself, and the method for calculating the Nikkei Stock Average and the like. All ownership of trademarks and any other intellectual property rights with respect to marks representing "Nikkei Inc.," "Nikkei," and "Nikkei Stock Average" belongs to Nikkei. Nikkei is not obliged to continuously publish the Nikkei Stock Average, nor is it liable for any error or delay in, or discontinuation of the publication thereof. Nikkei owns the right to change the content of the Nikkei Stock Average, such as the calculation method thereof, and the right to suspend the publication thereof. Nikkei does not give any warranty, nor is it responsible for any and all financial instruments and the like, which are based on, or otherwise refer to, the Nikkei Stock Average.
All rights in the FTSE China A50 Index (the “Index”) vest in FTSE International Limited (“FTSE”). “FTSE®” is a trademark of the London Stock Exchange Group companies and is used by FTSE under license.
The SGX FTSE China A50 Index Futures (the "Product") has been developed solely by Singapore Exchange Derivatives Trading Limited. The Index is calculated by FTSE or its agent. FTSE and its licensors are not connected to and do not sponsor, advise, recommend, endorse or promote the Product and do not accept any liability whatsoever to any person arising out of (a) the use of, reliance on or any error in the Index or (b) investment in or operation of the Product. FTSE makes no claim, prediction, warranty or representation either as to the results to be obtained from the Product or the suitability of the Index for the purpose to which it is being put by Singapore Exchange Derivatives Trading Limited.
Futures or options contract on any MSCI Index are not sponsored, guaranteed, endorsed, sold or promoted by MSCI, any affiliate of MSCI or any other party involved in, or related to, making or compiling any indexes (but expressly including the exchange) MSCI bears no liability of any kind with respect to such contracts